Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medical Marijuana
  • Medigap Premiums
  • Food Stamp Work Rules
  • Patients in ICE Custody
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Medical Marijuana
  • Medigap Premiums
  • Food Stamp Work Rules
  • Patients in ICE Custody
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Aug 19 2020

Full Issue

In Lawsuit, West Virginia Blames CVS, Walmart For State's Opioid Problem

Other pharmaceutical companies in the news include Teva, Reliance and Netmeds.

The Hill: West Virginia Sues CVS, Walmart For Aiding Opioid Epidemic 

West Virginia's attorney general filed lawsuits Tuesday against Walmart and CVS, alleging the companies helped create the state's devastating opioid epidemic. Patrick Morrisey, a Republican, said in separate lawsuits that the companies should remediate what has become a public health and financial crisis. (Weixel, 8/18)

Also —

Stat: DOJ Alleges Teva Used Charities To Pay Kickbacks To Medicare Patients

Federal authorities alleged that Teva Pharmaceuticals (TEVA) donated hundreds of millions of dollars to a pair of foundations, but the payments were actually kickbacks to Medicare patients and designed to cover their out-of-pocket costs for a pricey medicine. In a lawsuit filed in federal court in Boston, the Department of Justice accused the drug maker of paying hundreds of millions of dollars to the charities — the Chronic Disease Fund and The Assistance Fund — to ensure that, from 2006 through 2015, Medicare patients did not have to make a co-payment or deductible for the Copaxone multiple sclerosis drug. (Silverman, 8/18)

Reuters: Reliance Buys Majority Stake In Online Pharmacy Netmeds For $83 Million 

India’s Reliance Industries Ltd has bought a majority stake in online pharmacy Netmeds for 6.2 billion rupees ($83 million), facing up to Amazon.com in the competition for the country’s fast-expanding online drug market. The deal will give the oil-to-telecoms conglomerate a 60% stake in Netmeds, which sells both over-the-counter medication and more than 70,000 prescriptions drugs, Reliance said here late on Tuesday. (Ravikumar, 8/18)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF